Kartos Therapeutics is dedicated to the development of novel, targeted therapeutics that meaningfully improve the lives of patients with cancer. Self-described as focusing on the MDM2-p53 interaction for treatment options across selected solid tumors and hematological malignancies.

Kartos Therapeutics

Kartos Therapeutics, Inc. | 3,821 followers on LinkedIn. Dedicated to the development of novel, targeted therapeutics that meaningfully improve the lives of patients with cancer | Kartos Therapeutics is a privately held, clinical-stage biopharmaceutical company developing a potentially best-in-class MDM2 inhibitor. Launched in 2018 by proven industry veterans, we are a passionate team based in Redwood City, California, and Bellevue, Washington. We have brought together scientists and clinicians with a deep understanding of hematology and oncology and an experienced leadership team.

Roger Ulrich

SVP Clinical Pharmacology at Kartos Therapeutics

Greg Slatter

Pharma/Biotech Executive; Independent Board Director

Flavia Borellini

Kimberly Price

Kartos Therapeutics, Inc.

Feb 29th is #RareDiseaseDay and Kartos encourages you to learn more about the global movement that champions the cause of people living with rare diseases like #myelofibrosis .

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Nov 9, 2024 9:57 PM	98d6e076
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 9, 2024 9:57 PM	fde3f89d
crunchbase trigger	general	Nov 27, 2024 12:50 PM	c897a6e0
crunchbase profile	general
li profile	general	Nov 9, 2024 9:57 PM	90b7d736
translate crunchbase fundingrounds	general
peers	general	Nov 9, 2024 9:57 PM	45cecee0
news basic	general	Nov 9, 2024 9:57 PM	1963353d
bundesanzeiger	filings
financials download nd	financials
private financials	financials

KART

COM:KARTOSTHERA

Kartos Therapeutics